首都医科大学附属北京世纪坛医院

测试版

多云 12℃~24℃ 风向:南风微风级
路径导航: 首页 >> 专家介绍 >> 钟晓松

钟晓松主任医师

职务:主任

擅长:

1. 肿瘤特异性细胞免疫治疗(CAR-T 和TCR-T)

2. 基因治疗

3. 记忆干细胞样记忆T 细胞(Tscm)

4. 肿瘤分子诊断

更多>>

个人简介 学术任职 主研方向 获奖情况 学术论著

[职称] 教授,博士生导师

[职务] 临床基因和细胞工程中心主任

[学位] 博士

教育背景

1996,上海交通大学医学硕士

2011,美国马里兰州大学医学院生物统计学硕士

工作经历

2015.10-至今 首都医科大学世纪坛医院,国家二级教授,海外特聘专家,武汉大学和首都医科大学海外特聘教授。

2012.01-2015.09 终生高级研究员,美国国防部疾病卫生监督中心。

2012.01-2016.05 兼职高级研究员,美国食品和药物管理局(FDA)。

2009.04-2012.01 首席研究员,美国食品和药物管理局(FDA)。

2006.03-2009.03 高级研究员(Dr.Rosenberg Steven 实验室),美国国家癌症研究所(NCI),美国国立卫生研究(NIH),国际上过继T细胞免疫治疗的创始人和领导者。

2003.03-2006.02 研究员(Dr.Sadelain Michel实验室),纪念斯隆 - 凯特琳癌症中心肿瘤免疫细胞和基因治疗中心(MSKCC),美国细胞和基因治疗协会主席(2013-今年)国际基因和细胞治疗的领军人物。

2001.02-2003.02 博士后研究员(Dr.Eddie Reed 实验室 ) MBR Cancer Center,UNIVERSITY Of WEST VIRGINIA,USA。

1999.07-2001.01 高级访问学者(Dr.Eddie Reed 实验室) 美国国家癌症研究所(NCI),美国国立卫生研究院。

1997.06-1999.06 助理研究员,上海肿瘤研究所,WHO 肿瘤合作研究中心。

1996.06-1997.05 实习研究员,上海肿瘤研究所,WHO 肿瘤合作研究中心。

联系方式

联系电话:63926418

中国医师协会脑胶质瘤专业委员会委员

北京免疫协会常务理事

中国抗癌协会肿瘤生物治疗专业委员会委员

中国肿瘤临床常务编审

美国基因和细胞治疗协会(ASGCT)终身会员

美国癌症协会(AACR)终身会员

国际干细胞研究协会会员(ASSCR)

肿瘤诊断和特异性免疫治疗(CAR-T 和 TCR-T)以及常见遗传性疾病的基因诊断和基因治疗(地中海贫血和其它的代谢性遗传疾病)。

赢得FDA临床药物转化奖(2012年)

上海科技第三等奖(1999年)

上海卫生系统杰出青年学者奖(1997年)

主要论文

1. Brief report: Rate of prescriptions by therapeutic classification, active component, U.S. Armed Forces, 2014. Hurt L,Zhong X S. MSMR 2015 Sep;22(9):12-5.

2. DH Park, J  Park , Zhong XS ,Sadelain M. Robust estimation of null distribution in local false discovery rate methods and application to gene selection. Computational Statistics and Data Analysis  2011,July,2421-2432.

3. Wnt signaling regulates T cell differentiation and promotes the generation of CD8+ memory stem cells. Zhong* XS, Gattinoni* L, Palmer DC, Hinrichs CS, Yu Z, Wrzesinski C, Paulos CM, Cassard, Boni A,Muranski P, Robbins PF, Rosenberg SA, Restifo NP. Nature Medicine 15(7): 808-13,2009. (Comments in NATURE REVIEW|IMMUNOLOGY  2009 JULY and Nature Medicine 15(6):731, 2009)

4. Zhong et al: "Integrated CD28 and 4-1BB Signals Strongly Potentiate CD8+ T Cell Mediated Eradication on Metastatic Prostate Cancer" Molecular Therapy, vol. 13, 2006, p. S103.

5. Zhong XS , Maiko Matsushita, Jason Plotkin, Isabelle Riviere, Michel Sadelain Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment antigen-induced  PI3kinase/AKT/BclXL activation and human primary CD8+ T cell-mediated tumor elimination.  Mol Ther. 2010 Feb;18(2):413-20. Epub 2009 Sep 22.)

6. Zhao Yangbing, Qiong J, Wang, Xiao-Song Zhong, Michel Sadelain, ZeligEshhar,Steven  A.Rosenberg,RichardA.Morgan.A Herceptin-based CAR with modified signaling domains leads to enhanced  survival of transduced T lymphocytes and  anti-tumor activity.  Journal of Immunology. 2009 Nov 1:183(9):5563-74.

7. Gade*T, Hassen*W, Santos* E, Gunset G, Gong MC, Brentjens R, Zhong XS, Stephan M, Osborne J, Hall S, Heston  WD, LarsonS, Koutcher JA and Sadelain M.Targeted Elimination of prostate cancer by genetically directed human peripheral blood T lymphocytes.  Cancer Res. Oct 1;65(19):9080-8. 2005 .

8. Zhong XS, Liu LZ, Skinner HD, Cao Z, Ding M, Jiang BH Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human  ovarian cancer cells.. Biochem  Biophys Res Commun. 2007 Jun 22;358(1):92-8.

9. Yan QW, Reed E,Zhong XS, Thornton K, Guo Y, Yu JJ.MZF1 possesses a repressively regulatory function in ERCC1 expression.,  Biochem Pharmacol. 2006 Mar 14;71(6):761-71. Epub 2006 Jan 19.

10. Zhong XS, Qian Y, Flynn DC, Zheng JZ, Qiao M, Wu C, Dedhar S, Shi X, Jiang BH. ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene. 2005 Apr 28;24(19):3154-65. 

11. Zhong XS, Zheng JZ, Reed E, Jiang BH. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80.

12. Gao N, Flynn DC, Zhang Z,  Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH 。G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.. Am J Physiol Cell Physiol. 2004  Aug;287(2):C281-91. Cited by 36 PubMed Central articles.

13. Skinner  HD, Zhong XS, Gao N, Shi X, Jiang BH. 。Arsenite induces p70S6K1 activation and HIF-1alpha expression in prostate cancer cells. Mol Cell Biochem. 2004 Jan;255(1-2):19-23.

14. Huang C, Li J, Ke Q, Leonard SS, Jiang BH, Zhong XS, Costa M, Castranova V, Shi X Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C..Cancer Res. 2002 Oct 15;62(20):5689-97.

15. Zhong XS, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E,  Li QQ Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells.. Int J Oncol. 2004 Aug;25(2):445-51.

16. Zhong XS, Li QQ, Reed E 。SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair.. Cell Mol Life Sci. 2003 Apr;60(4):794-802.

17. Li QQ, Yunmbam MK, Zhong XS, Yu JJ, Mimnaugh EG, Neckers L, Reed E Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.. Cell Mol Biol (Noisy-le-grand). 2001;47.

18. Zhong XS, Thornton K, Reed E Computer based analyses of the 5'-flanking regions of selected genes involved in the  nucleotide excision repair complex. Int J Oncol. 2000 Aug;17(2):375-80.

19. Mutation of P53 detection by PCR-SSCP in Hematological Oncology.  Chen DM, Li  XG, Zhong XS.  Journal of Clinical Hematology. 2001;2:68-71.

20. Nicotine Prolongs the survival of rat macrophages by inhibiting its apoptosis. Wang CH ,Liu ZL, Zhong XS. Acad J Sci Mil Med Univ.2000 20: 974-976.

21. Homozygous detection of MTS2/p15 gene in primary non-small cell lung cancer. Xu KL, Zhong XS, Li  ML.Tumor(Shanghai) 1999:1-3.

22. Allele-specific chromosome 3p25 deletion detected by PCR-LOH analysis in primary non-small cell lung cancer. Journal of Lung Cancer (China) . Guan SF, Zhong XS, Xu KL.1998;1:35-37.

23. Deletion of p16 gene in non-small cell lung cancer. Zhong XS, Xu KL, Liao ML. Tumor(Shanghai),1997;17:81-83.

24. Comparison of apoptosis fluorescence staining assay and MTT assay in the antitumor drug sensitivity test. Zhong XS, Zhang XH, Tong SQ, Lu DY. The Journal of Cancer Biotherapy (China) 1997;2:125-129.

25. A new approach for the measurement of TIL cytoxicity using apoptosis florescence staining assay. Zhong XS ,Tong SQ, Lu DY. Shanghai Medicine.1997;6:239-242.

26. Detection  of P53 gene mutation in non-small cell lung cancer by PCR-SSSP analysis. Zhong XS, Guan SF,XU KL. Cancer Research on Prevention and  Treatment(China).1997;24:131-133.

27. Homozygous deletion of P16 gene in human primary epithelial ovarian neoplasm. Zhong GL, Yang HJ, Xu KL, Zhong XS. The Journal of Clinical Oncology.1997;2:1-3.

28. The Advance of IL-2 (IL-2R) mRNA. Wu XQ, Zhong XS, Zhong J. Immunology Review. 1994;6:368-370.

著作译作

《细胞死亡及清除》崔天盆主编 中国科技出版社 2015